Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources | International Journal
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial
Practical Management of Anticoagulation in Patients With Atrial Fibrillation - ScienceDirect
Comparison of clinical trial major and clinically relevant nonmajor... | Download Table
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
MASTER DAPT | Terumo Interventional Systems
PPT - John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA Lars Wallentin, MD, PhD Uppsala Clinical R PowerPoint Presentation - ID:154927
Nephrology Journal Club on X: "T1h: Outcomes were defined accordingly with International Society on Thrombosis and Haemostasis @isth #NephJC https://t.co/b0tQMjYKbE" / X
Predictive ability of scores for bleeding risk in heart disease outpatients on warfarin in Brazil | PLOS ONE
Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: A systematic review and a proposal from the ISTH SSC - Tardy - 2019 - Journal of Thrombosis and
MASTER-DAPT: “the MASTER of high-bleeding risk trials”
Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials | Scientific Reports
Long-Term Risk of Clinically Relevant Non-Major Bleeding During Extended Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis - ISTH Congress Abstracts
Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial | Scientific Reports
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor - ScienceDirect
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial | Haematologica
Frontiers | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Supplementary file 2. Primary and secondary outcomes
Risk of adverse outcomes after clinically relevant non-major bleeding | Download Scientific Diagram
Cancers | Free Full-Text | A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal,
Direct Oral Anticoagulants: A User's Guide | Consultant360
Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry | Journal of Thrombosis and Thrombolysis
PPT - DVT Prophylaxis in Orthopedic Patients PowerPoint Presentation, free download - ID:2670969
Assessing Bleed Severity and Managing Major and Non-Major Bleeds | Download Scientific Diagram
abelacimab for prevention of venous | PPT
Were Major Bleeds Defined in the Same Way - Novel Oral Anticoagulants - Recent Advances in Oral Anticoagulation Therapy for Patients with Atrial Fibrillation
